)
)
)
Consano Bio
Consano Bio is a clinical-stage biotechnology company advancing a novel therapeutic designed to address serious pain conditions where conventional therapies are limited or ineffective.
Its lead investigational program, C-1101, is being developed as a potential first-in-class, non-opioid pharmaceutical therapy for chronic lumbosacral radiculopathy (LSR), more commonly known as chronic sciatica.
What is your next catalyst (value inflection) update?
Completion of phase I study of patients with Chronic LSR, placebo-controlled measures include safety, efficacy and exploratory markers of disease
Year Founded
2023
Lead Product in Development
C-1101 is Consano Bio’s lead investigational therapy designed to treat chronic painful lumbosacral radiculopathy (LSR), or chronic sciatica.
C-1101 is a purified, multi-protein solution derived from human platelets in plasma collected from healthy donors. The product contains consistent concentrations of cytokines, growth factors, and matrix proteins to help trigger the body’s natural healing response.
Delivered via an epidural injection, C-1101 provides supraphysiologic concentrations of these proteins directly to the site of nerve injury. Through this targeted delivery, C-1101 is intended to:
Modulate inflammation and promote reparative inflammation.
Promote cellular proliferation and repair through platelet-derived growth factors.
Development Phase of Lead Product
Phase I
CEO/Top Company Official
Andrew Hall
When you expect your next catalyst update?
Q4 2026, clinical data
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
